At the news
? BEARISHIMPACT 7/10 COURT-RULING filed Jun 3, 2026 at 20:00 ET
The Supreme Court unanimously reversed the Federal Circuit, holding that Amarin failed to state a claim for induced infringement against Hikma's generic icosapent ethyl (Vascepa). The decision clarifies that generic manufacturers' compliance with labeling requirements and standard industry practices does not constitute active inducement, effectively dismissing Amarin's lawsuit and removing a key legal barrier to generic competition.
- SCOTUS ruled that Amarin's induced infringement complaint failed to plausibly allege active steps encouraging infringement.
- The Court rejected the Federal Circuit's 'could be read as instruction' standard, requiring affirmative statements or actions.
- Hikma's skinny label, patient leaflet, website, and press releases were deemed lawful or too vague to support inducement.
- The ruling allows Hikma to continue marketing generic icosapent ethyl for the severe hypertriglyceridemia (SH) indication without induced infringement liability based on these statements.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access